Description:
Tofacitinib is a small-molecule targeted synthetic DMARD. It was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling (inhibition of janus kinases). Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. The drug may be used in combination with methotrexate or another conventional synthetic DMARD or in monotherapy. It inhibits radiographic progression of the disease. Also it has a safety profile of more than 9.5 years.
Share your experience with our medical product. Write a review!
22 Jul 2026
International Yoga Day 2026: How Yoga Promotes Wellness, Wisdom & Inner Peace
Yoga is more than a form of physical exercise. It is a holistic practice that connects the body, mind, and breath to support overall wellbeing. Every year, International Yoga Day encourages people aro
15 Jul 2026
World Brain Tumor Day 2026: Early Detection Awareness and the Need to Reduce Diagnostic Delays
World Brain Tumor Day is observed annually on 8 June to raise awareness about brain tumours, encourage early diagnosis, and support patients and families affected by these complex conditions.
15 Jun 2026
Hetero Healthcare on World No Tobacco Day 2026 - Unmasking the Appeal, Countering Addiction
Every year on May 31, the world comes together to observe World No Tobacco Day, a global initiative aimed at raising awareness about the dangers of tobacco use.
01 Jun 2026
Salt, Stress, and Sedentary Life: The Three Big Triggers of Hypertension
Every two seconds, somewhere in the world, a person suffers a heart attack or stroke linked to uncontrolled blood pressure.
